Palisade Bio (PALI) Other Non-Current Assets (2010 - 2026)
Palisade Bio (PALI) reported Other Non-Current Assets of $17000.0 for Q1 2026, down 34.62% year-over-year from $26000.0 in Q1 2025, and down 75.0% on a QoQ basis from $68000.0 in Q4 2025.
Palisade Bio (PALI) has 17 years of Other Non-Current Assets data on file, last reported at $17000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 34.62% year-over-year to $17000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17000.0 (down 34.62% YoY) and the FY2025 annual result came in at $68000.0, up 161.54% from the prior year.
- Other Non-Current Assets fell to $17000.0 in Q1 2026 per PALI's latest filing, from $68000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $746000.0 in Q3 2022 and bottomed at $12000.0 in Q4 2023.
- The 5-year median for Other Non-Current Assets is $26000.0 (2022), against an average of $127937.5.
- The widest annual swing landed in 2022, when Other Non-Current Assets soared 2769.23%; it then plunged 97.26% in 2024.
- Tracing PALI's Other Non-Current Assets over 5 years: stood at $26000.0 in 2022, then plunged by 53.85% to $12000.0 in 2023, then soared by 116.67% to $26000.0 in 2024, then soared by 161.54% to $68000.0 in 2025, then tumbled by 75.0% to $17000.0 in 2026.
- Per Business Quant, the three latest PALI Other Non-Current Assets figures stand at $17000.0 (Q1 2026), $68000.0 (Q4 2025), and $171000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | 17,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,000.00 |
| Dec 31, 2025 | 68,000.00 |
| Jun 30, 2025 | 171,000.00 |
| Mar 31, 2025 | 26,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Sep 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 375,000.00 |
| Mar 31, 2024 | 26,000.00 |
| Dec 31, 2023 | 12,000.00 |
| Sep 30, 2023 | 438,000.00 |
| Jun 30, 2023 | 26,000.00 |
| Mar 31, 2023 | 26,000.00 |
| Dec 31, 2022 | 26,000.00 |
| Sep 30, 2022 | 746,000.00 |
| Jun 30, 2022 | 26,000.00 |
| Mar 31, 2022 | 26,000.00 |
| Dec 31, 2021 | 868,000.00 |
| Sep 30, 2021 | 26,000.00 |
| Jun 30, 2021 | 26,000.00 |
| Mar 31, 2021 | 860,702.00 |
| Dec 31, 2020 | 26,000.00 |
| Sep 30, 2020 | 899,538.00 |
| Jun 30, 2019 | 36,901.00 |
| Mar 31, 2019 | 53,354.00 |
| Dec 31, 2018 | 23,965.00 |
| Sep 30, 2018 | 28,475.00 |
| Jun 30, 2018 | 33,004.00 |
| Mar 31, 2018 | 18,048.00 |
| Dec 31, 2017 | 13,853.00 |
| Sep 30, 2017 | 13,719.00 |
| Jun 30, 2017 | 13,696.00 |
| Mar 31, 2017 | 15,824.00 |
| Dec 31, 2016 | 15,662.00 |
| Sep 30, 2016 | 49,984.00 |
| Jun 30, 2016 | 57,916.00 |
| Mar 31, 2016 | 57,692.00 |
| Dec 31, 2015 | 71,797.00 |
| Sep 30, 2015 | 72,163.00 |
| Jun 30, 2015 | 40,830.00 |
| Mar 31, 2015 | 59,098.00 |
| Dec 31, 2014 | 58,713.00 |
| Sep 30, 2014 | 57,720.00 |
| Jun 30, 2014 | 58,859.00 |
| Mar 31, 2014 | 248,688.00 |
| Dec 31, 2013 | 360,848.00 |
| Sep 30, 2013 | 64,862.00 |
| Jun 30, 2013 | 59,568.00 |
| Mar 31, 2013 | 725,228.00 |
| Dec 31, 2012 | 59,568.00 |
| Sep 30, 2012 | 59,533.00 |
| Jun 30, 2012 | 59,063.00 |
| Mar 31, 2012 | 75,394.00 |
| Dec 31, 2011 | 75,394.00 |
| Sep 30, 2011 | 68,655.00 |
| Jun 30, 2011 | 68,653.00 |
| Dec 31, 2010 | 60,875.00 |